# Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers

> **NCT00832091** · PHASE2 · COMPLETED · sponsor: **RegeneRx Biopharmaceuticals, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Venous Stasis Ulcers

## Interventions

- **DRUG:** Thymosin Beta 4
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00832091
- **Lead sponsor:** RegeneRx Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2010-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00832091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00832091, "Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00832091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*